[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasodilation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasodilation":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,90,119,148,179,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100479368","reducing-blood-pressure-in-mid-life-adult-binge-drinkers-100479368",false,"NCT05522075","Reducing Blood Pressure in Mid-life Adult Binge Drinkers","Reducing Blood Pressure in Mid-life Adult Binge Drinkers: the Role of Microvascular Function and Sympathetic Activity","Inclusion Criteria:\n\n* Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink\n* Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr).\n* Subjects who can speak and understand English.\n\nExclusion Criteria:\n\n* a history of diabetes, cardiovascular disease, liver, or renal disease\n* current or history of smoking and illicit drug use\n* blood pressure ≥160\u002F100 mm Hg\n* other known traditional cardiovascular disease risks: obesity (BMI≥35 kg\u002Fm2), or hyperlipidemia (total cholesterol\\>230 mg\u002Fdl and\u002For LDL cholesterol\\>160 mg\u002Fdl)\n* active infection (in the past 2 months)\n* a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid)\n* unstable body weight (\\>5% change during the past 6 months)\n* regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week)\n* current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)",true,"ALL","50 Years","64 Years",{"count":21,"type":22},55,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study has two phases:\n\nPhase 1 is to examine blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers vs. alcohol abstainers\u002Fmoderate drinkers.\n\nPhase 2 is to examine the effect of 8-week aerobic exercise training on blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers",[28,29,30,31,32,33,34,35],"Alcohol Drinking","Binge Drinking","Blood Pressure","Alcohol Abstinence","Aging","Lifestyle Factors","Vasodilation","Behavioral Problem",[37,38,39,40,41,42],"Exercise training","High-intensity interval training","Midlife adults","Middle-aged","Microvascular function","Sympathetic nerve activity","RECRUITING","2026-05-27",{"date":46,"type":47},"2026-06-01","ACTUAL",{"date":49,"type":47},"2022-11-21",{"date":51,"type":22},"2027-04-30",{"name":53,"class":54},"The University of Texas at Arlington","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":77,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":55},"100538429","phase-2-vasodilator-and-exercise-study-for-dmd-vaso-rex-100538429","NCT06290713","Vasodilator and Exercise Study for DMD (VASO-REx)","Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)","Inclusion Criteria:\n\n* Diagnosis of DMD confirmed by genetic report\n* Minimum entry age of 6.0 years old\n* Ambulatory\n* On stable glucocorticoid regimen (for \\> 3 months)\n\nExclusion Criteria:\n\n* Contraindication to a Magnetic resonance Imaging examination (e.g. severe claustrophobia, magnetic implants, unable\u002Funwilling to perform test)\n* Presence of unstable medical problems, including severe cardiomyopathy, left ventricular ejection fraction \\\u003C45%, cardiac conduction abnormalities as evidenced on ECG, uncontrolled seizure disorder, uncontrolled hypo or hypertension\n* Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g., myasthenia gravis, endocrine disorder, mitochondrial disease)\n* Presence of a secondary condition leading to developmental delay or impaired motor control (e.g., cerebral palsy) or previous history of unprovoked rhabdomyolysis\n* Contraindications to phosphodiesterase 5 inhibitors (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5 inhibitors) or other medications known to modulate blood flow or muscle metabolism\n* Participation in currently approved FDA trials or other investigational clinical trials during the period of the study","MALE","6 Years",{"count":66,"type":22},50,[68],"PHASE2","Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.",[71,72,73,74,34,75,76],"Duchenne Muscular Dystrophy","Duchenne Disease","Muscular Dystrophy","Muscular Dystrophy in Children","Exercise","DMD",[76,78,79,80],"Tadalafil","Drug and Exercise Intervention","Treatment Strategy","2026-05-12",{"date":83,"type":47},"2026-05-15",{"date":85,"type":47},"2024-06-05",{"date":87,"type":22},"2026-11",{"name":89,"class":54},"University of Florida",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":55},"100301374","red-light-treatment-in-peripheral-artery-disease-100301374","NCT03203239","Red Light Treatment in Peripheral Artery Disease","Vasodilatory Effects of Light on Peripheral Artery Disease","Inclusion Criteria:\n\n* Participants will be subjects between the ages of 18 and 85 who have been diagnosed with peripheral artery disease. Men and women will be recruited for participation. All ethnicities will be included in this study.\n\nDiagnosis of peripheral artery disease is defined as an Ankle Brachial index of \\\u003C0.9 or greater than 1.1 either at rest or during treadmill exercise.\n\nExclusion Criteria:\n\n* Exclusionary criteria include age under 18 years and over 85 years, those who are unable to understand the consent process , those who cannot read or speak English, active pregnancy, hypersensitivity to perflutren contrast agents, pulmonary hypertension, active illicit drug use, untreated blood pressure over 160\u002F95, sickle cell disease, or a history of intracardiac shunt. Additional exclusion criteria neurological diseases such as spinal stenosis, unspecified pain disorders, and any uncontrolled medical conditions.","18 Years","85 Years",{"count":100,"type":22},40,[25],"Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\\\u003C.9 or \\>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.",[104,105,34],"Peripheral Artery Disease","Claudication, Intermittent",[107,108,109],"red light","vasodilation","nitric oxide","2026-04-27",{"date":112,"type":47},"2026-05-01",{"date":114,"type":47},"2018-01-17",{"date":116,"type":22},"2028-12-31",{"name":118,"class":54},"University of Alabama at Birmingham",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":97,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":55},"100515916","phase-4-sympathetic-neurovascular-transduction-role-of-adrenergic-receptors-and-sex-differences-100515916","NCT05997732","Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences","STARS","Inclusion Criteria:\n\n* Between ages 18-40 years\n* No diagnosed medical history of cardiovascular, respiratory, nervous system, or metabolic disease.\n* Females must be pre-menopausal.\n* Prior to study visit: abstained from caffeine, alcohol, strenuous exercise, and medication not taken regularly for at least 12 hours.\n\nExclusion Criteria:\n\n* Current diagnosis of cardiovascular, respiratory, nervous system, or metabolic disease that may impact blood pressure regulation. This will be assessed on a case-by-case basis by the study physician.\n* Participants with bleeding or clotting disorders, or those currently taking blood thinners.\n* Participants currently taking beta-agonist inhalers i.e. Ventolin (at least not in the last 24 hours).\n* Females who are pregnant, confirmed by a pregnancy test.\n* Females who have are less than 1 year postpartum or are breastfeeding.\n* Females who are post-menopausal.\n* Participants that are classified as obese (body mass index \\> 30 kg ⋅ m2).\n* Have a history of smoking regularly in the last 6 months (but nicotine substitutes (i.e. patch, gum) are not an exclusion criteria).\n* Those with a known allergy to sulfites, or other components of the supplied solution of study drugs.\n* Participants taking medications that are contraindicated with any of the study drugs, such as monoamine oxidase (MAO) inhibitors or tricyclic antidepressants.\n* Participants who have not adhered to the pre-testing guidelines related to diet, alcohol or exercise will not be excluded, but will be rescheduled for a different day. This is to reduce experimental variability.","40 Years",{"count":128,"type":22},30,[130],"PHASE4","The main purpose of this interventional study is to examine differences in resting blood pressure control between healthy males and females. The main questions it aims to answer are:\n\n1. Are there sex differences in the communication between the sympathetic nervous system (also known as the \"fight or flight\" response) and peripheral blood vessels (which influence systemic blood pressure)?\n2. What is the role of specific vascular receptors that respond to sympathetic signals, and is it different between males and females?\n\nParticipants will complete one study visit of approximately 3 hours where they will:\n\n* Have a blood sample taken to measure circulating sex hormone and sympathetic transmitters.\n* Receive very small doses of medications commonly used to adjust blood pressure through an artery in their arm. The effects of these medications will be short-acting and localized to the forearm.\n* Have their sympathetic nervous activity directly measured through two very small needles (similar to acupuncture needles) in the side of their leg.\n* Have their blood pressure and heart rate recorded, and forearm blood flow measured using ultrasound.",[133,34],"Vasoconstriction",[135,136,137,138],"sympathetic nerve activity","sex differences","adrenergic receptors","neurovascular transduction","2026-01-05",{"date":141,"type":47},"2026-01-08",{"date":143,"type":47},"2023-10-31",{"date":145,"type":22},"2027-12-01",{"name":147,"class":54},"University of Alberta",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":16,"sex":17,"minAge":97,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":164,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":55},"100584862","effects-of-lentil-protein-hydrolysate-on-blood-pressure-control-vascular-function-and-exercise-performance-100584862","NCT06894875","Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance","Examining the Safety and Tolerability of Lentil Protein Hydrolysate in Healthy Males and Females Whilst Exploring the Effects of a Dose Range on Blood Pressure Control and Vascular Function and Exercise Performance","Inclusion Criteria:\n\n* Willing to provide written and dated informed consent to participate in the study.\n* Willing and able to comply with the protocol.\n* Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.\n* Male or female between 18 and 45 years of age (18.5 kg\u002Fm2 ≥ BMI \\\u003C 30 kg\u002Fm2).\n* Comply with ACSM guidelines for physical activity.\n* Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period.\n* Agree to not significantly alter diet or exercise routine during the trial period.\n* Willing to wear a wearable device continuously for the duration of the study\n\nExclusion Criteria:\n\n* Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.\n* Subjects with a history of alcohol and\u002For other drug abuse in the past year.\n* Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).\n* Consuming \\>14 alcoholic drinks per week or \\> 2 drinks\u002Fday in the 48 hours preceding a clinic visit.\n* Active smokers, nicotine use or vaping\n* Subjects suffering from a sleep disorder and\u002For who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and\u002For confounded the results of the study.\n* Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.).\n* Subjects with an elevated resting heart rate (\\>100 bpm) or blood pressure (systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg).\n* Pregnant or lactating women\n* Presentation of orthostatic hypotension during the screening and familiarisation study visit\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.","45 Years",{"count":157,"type":22},48,[25],"Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance",[75,30,34,161,162,163],"Vascular Function in Healthy Volunteers","Exercise Performance","Safety and Tolerability in Healthy Volunteers",[165,166,167,168],"Exercise performance","Vascular function","blood pressure control","Lentil protein hydrolysate","2025-12-15",{"date":171,"type":47},"2025-12-16",{"date":173,"type":47},"2025-06-24",{"date":175,"type":22},"2026-03-30",{"name":177,"class":178},"Nuritas Ltd","INDUSTRY",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":16,"sex":185,"minAge":97,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":55},"100548144","early-phase-1-impact-of-early-aging-and-menopause-on-the-vascular-responses-to-hypoxia-100548144","NCT06417177","Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia","Inclusion Criteria:\n\n* Female assigned at birth\n* Pre, peri- or post-menopausal\n* Healthy weight (BMI ≥18 and ≤30 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Male (assigned at birth)\n* Pregnancy, breastfeeding\n* Use of hormone replacement therapies\n* Hysterectomy\n* Body mass index \\>30 kg\u002Fm2\n* Diagnosed sleep apnea\n* Current smoking\u002FNicotine\u002FDrug use\n* Nerve\u002Fneurologic disease\n* Cardiovascular, hepatic, renal, respiratory disease\n* Blood pressure ≥140\u002F90 mmHg\n* Diabetes, Polycystic ovarian syndrome\n* Communication barriers\n* Prescription medications\n* Malignant cancer","FEMALE","70 Years",{"count":188,"type":22},75,[190],"EARLY_PHASE1","The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.",[32,193,194,34],"Menopause","Hypoxia","2025-09-08",{"date":197,"type":47},"2025-09-09",{"date":199,"type":47},"2024-06-03",{"date":201,"type":22},"2026-07",{"name":203,"class":54},"University of Missouri-Columbia",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":16,"sex":17,"minAge":97,"maxAge":155,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":55},"100456147","early-phase-1-sex-disparities-in-hypoxic-vasodilation-and-impact-of-obesity-100456147","NCT05219799","Sex Disparities in Hypoxic Vasodilation and Impact of Obesity","Inclusion Criteria:\n\n* BMI \\>18 kg\u002Fm2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Diagnosed sleep apnea or AHI \\>10 events\u002Fhr\n* Current smoking\u002FNicotine use\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy\n* Nerve\u002Fneurologic disease\n* Cardiovascular, hepatic, renal, respiratory disease\n* Blood pressure ≥140\u002F90 mmHg\n* Diabetes, Polycystic ovarian syndrome\n* Communication barriers\n* Prescription medications, Sensitivity to lidocaine",{"count":211,"type":22},72,[190],"The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.",[215,34,216],"Obesity","Healthy","2025-05-22",{"date":219,"type":47},"2025-05-29",{"date":221,"type":47},"2023-03-14",{"date":223,"type":22},"2026-06-30",{"name":203,"class":54}]